title: Induction of protective and therapeutic anti-cancer immunity by using bispecific anti-idiotype antibody G22-I50 for nasopharyngeal carcinoma.
abstract: Increasing evidence has suggested that bispecific and multivalent antibodies which have more antigen binding sites will improve their immunogenicity. The bispecific anti-idiotype antibody vaccine G22-I50 was obtained through genetic engineering to enhance the immunogenicity of anti-idiotype antibody vaccines G22 and I50. G22-I50 vaccination could induce anti-tumor immunity in the Balb/c mouse model. The protective and therapeutic efficacy of G22-I50 was also evaluated using the hu-PBL-SCID mouse model injected three times with G22-I50, G22, or I50 mixed with Freund's adjuvant. Results demonstrated that the protective anti-tumor effect of G22-I50 could be relevant with the production of Ab3 antibody and activation of CD8(+) cytotoxic T-lymphocytes. In preventive and therapeutic experiments, G22-I50 could reduce tumor size and prolong the survival time of HNE2-bearing mice (p<0.05). Human CD8(+) T lymphocytes infiltrated the tumor sites, and high levels of human IFN-γ, TNF-α, and caspase-3 were also detected in the tumors from G22-I50-vaccinated and -treated mice. Therefore, the bispecific anti-idiotype antibody vaccine G22-I50 can induce strong humoral and cell-mediated immune responses. This vaccine can be potentially applied to prevent and treat nasopharyngeal carcinoma.
authors: Clinical Laboratory, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu 610072, Sichuan Province, China; Tumor Immunobiology Laboratory of Cancer Research Institution, Central South University, Changsha 410078, Hunan Province, China. Electronic address: xywjj08@163.com.
authors: Jia-Jia
authors: JJ
authors: Wang
authors: Tumor Immunobiology Laboratory of Cancer Research Institution, Central South University, Changsha 410078, Hunan Province, China.
authors: Yan-Hong
authors: YH
authors: Liu
authors: Tumor Immunobiology Laboratory of Cancer Research Institution, Central South University, Changsha 410078, Hunan Province, China.
authors: Guan-Cheng
authors: GC
authors: Li
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage*; D018033:Antibodies, Bispecific / Q000008:administration & dosage*; D019496:Cancer Vaccines / Q000008:administration & dosage*; D002277:Carcinoma; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D016513:Mice, SCID; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009368:Neoplasm Transplantation; D047368:Tumor Burden
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018033:Antibodies, Bispecific; D019496:Cancer Vaccines
keywords: Anti-idiotype antibody; Bispecific; Nasopharyngeal carcinoma; hu-PBL–SCID